Serotype-dependent transduction efficiencies of recombinant adeno-associated viral vectors in monkey neocortex
暂无分享,去创建一个
Zeger Debyser | Wim Vanduffel | Marie-Eve Laramée | Annelies Gerits | Pascaline Vancraeyenest | Samme Vreysen | Annelies Michiels | Rik Gijsbers | Chris Van den Haute | Lieve Moons | Veerle Baekelandt | Lutgarde Arckens | W. Vanduffel | L. Arckens | V. Baekelandt | L. Moons | C. Van den Haute | R. Gijsbers | Z. Debyser | M. Laramée | Pascaline Vancraeyenest | A. Michiels | A. Gerits | Samme Vreysen | Marie-Eve Laramée
[1] Edward S. Boyden,et al. A history of optogenetics: the development of tools for controlling brain circuits with light , 2011, F1000 biology reports.
[2] R. Mandel,et al. Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[3] Ilana B. Witten,et al. Recombinase-Driver Rat Lines: Tools, Techniques, and Optogenetic Application to Dopamine-Mediated Reinforcement , 2011, Neuron.
[4] Guoan Zheng,et al. An optical neural interface : in vivo control of rodent motor cortex with integrated fiberoptic and optogenetic technology , 2016 .
[5] J. Butler. Optogenetics: shining a light on the brain , 2012 .
[6] R. Mandel,et al. Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[7] G. Bormans,et al. Highly efficient multicistronic lentiviral vectors with peptide 2A sequences. , 2009, Human gene therapy.
[8] P. Aebischer,et al. Neuroprotection by gene therapy targeting mutant SOD1 in individual pools of motor neurons does not translate into therapeutic benefit in fALS mice. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[9] Kenneth P Vives,et al. Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[10] D. Hampson,et al. Transduction of the central nervous system after intracerebroventricular injection of adeno-associated viral vectors in neonatal and juvenile mice. , 2013, Human gene therapy methods.
[11] Gabriele Mittermeyer,et al. Axonal transport of adeno-associated viral vectors is serotype-dependent , 2012, Gene Therapy.
[12] Shu Wang,et al. CMV enhancer/human PDGF-β promoter for neuron-specific transgene expression , 2004 .
[13] S. Kügler,et al. Promoters and serotypes: targeting of adeno‐associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo , 2005, Experimental physiology.
[14] J. Gale,et al. Recombinant adeno-associated virus type 2 pseudotypes: comparing safety, specificity, and transduction efficiency in the primate striatum. Laboratory investigation. , 2011, Journal of neurosurgery.
[15] A. Toga,et al. The Rhesus Monkey Brain in Stereotaxic Coordinates , 1999 .
[16] Shuyun Dong,et al. Directed molecular evolution of DREADDs: a generic approach to creating next-generation RASSLs , 2010, Nature Protocols.
[17] P. Aebischer,et al. Direct and retrograde transduction of nigral neurons with AAV6, 8, and 9 and intraneuronal persistence of viral particles. , 2013, Human gene therapy.
[18] Philippe Hantraye,et al. Applications of lentiviral vectors for biology and gene therapy of neurological disorders. , 2008, Current gene therapy.
[19] I. Bièche,et al. Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate. , 2010, Human molecular genetics.
[20] S. Rumpel,et al. Analysis of Transduction Efficiency, Tropism and Axonal Transport of AAV Serotypes 1, 2, 5, 6, 8 and 9 in the Mouse Brain , 2013, PloS one.
[21] Philippe Hantraye,et al. Dopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia , 2009, Science Translational Medicine.
[22] Michael B. Stadler,et al. Encoding of conditioned fear in central amygdala inhibitory circuits , 2010, Nature.
[23] Karl Deisseroth,et al. Optogenetics in Neural Systems , 2011, Neuron.
[24] Donald W. Pfaff,et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain , 1994, Nature Genetics.
[25] Matthew T. Kaufman,et al. An optogenetic toolbox designed for primates , 2011, Nature Neuroscience.
[26] D. Watanabe,et al. Viral vector-mediated selective and reversible blockade of the pathway for visual orienting in mice , 2013, Front. Neural Circuits.
[27] Karl Deisseroth,et al. Optical activation of lateral amygdala pyramidal cells instructs associative fear learning , 2010, Proceedings of the National Academy of Sciences.
[28] K. Deisseroth,et al. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance , 2009, Nature.
[29] P. Pivirotto,et al. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[30] M. Moser,et al. Optogenetic Dissection of Entorhinal-Hippocampal Functional Connectivity , 2013, Science.
[31] David V Schaffer,et al. The AAV Vector Toolkit: Poised at the Clinical Crossroads. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[32] R. Guillery,et al. Functional organization of thalamocortical relays. , 1996, Journal of neurophysiology.
[33] Hong Yu Chen,et al. Oligodendrocyte‐specific gene expression in mouse brain: Use of a myelin‐forming cell type–specific promoter in an adeno‐associated virus , 1999, Journal of neuroscience research.
[34] A. Hendrickson,et al. Calcium‐binding proteins as markers for subpopulations of GABAergic neurons in monkey striate cortex , 1990, The Journal of comparative neurology.
[35] Anatol C. Kreitzer,et al. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry , 2010, Nature.
[36] P. Reier,et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[37] D. Watanabe,et al. Genetic dissection of the circuit for hand dexterity in primates , 2012, Nature.
[38] Jacob G. Bernstein,et al. Millisecond-Timescale Optical Control of Neural Dynamics in the Nonhuman Primate Brain , 2009, Neuron.
[39] Wim Vanduffel,et al. Optogenetics in primates: a shining future? , 2013, Trends in genetics : TIG.
[40] Dae-Shik Kim,et al. Global and local fMRI signals driven by neurons defined optogenetically by type and wiring , 2010, Nature.
[41] J. Betley,et al. Adeno-associated viral vectors for mapping, monitoring, and manipulating neural circuits. , 2011, Human gene therapy.
[42] G. Breese,et al. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector , 1996, Brain Research.
[43] W. Denk,et al. Lentivirus-based genetic manipulations of cortical neurons and their optical and electrophysiological monitoring in vivo , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[44] P Osten,et al. Viral vectors: a wide range of choices and high levels of service. , 2007, Handbook of experimental pharmacology.
[45] J. Feldon,et al. Transduction Profiles of Recombinant Adeno-Associated Virus Vectors Derived from Serotypes 2 and 5 in the Nigrostriatal System of Rats , 2004, Journal of Virology.
[46] Edward M. Callaway,et al. Short Promoters in Viral Vectors Drive Selective Expression in Mammalian Inhibitory Neurons, but do not Restrict Activity to Specific Inhibitory Cell-Types , 2009, Frontiers in neural circuits.
[47] J. Kordower,et al. Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[48] David R Williams,et al. Intravitreal injection of AAV2 transduces macaque inner retina. , 2011, Investigative ophthalmology & visual science.
[49] G. Orban,et al. Visual Motion Processing Investigated Using Contrast Agent-Enhanced fMRI in Awake Behaving Monkeys , 2001, Neuron.
[50] S. Wang,et al. CMV enhancer/human PDGF-beta promoter for neuron-specific transgene expression. , 2004, Gene therapy.
[51] T. Yamamori,et al. Comparative analyses of adeno-associated viral vector serotypes 1, 2, 5, 8 and 9 in marmoset, mouse and macaque cerebral cortex , 2015, Neurosciences research.
[52] Ren-Ke Li,et al. Human CMV immediate‐early enhancer: a useful tool to enhance cell‐type‐specific expression from lentiviral vectors , 2008, The journal of gene medicine.
[53] C. Gall,et al. Differential effects of monocular deprivation on glutamic acid decarboxylase and type II calcium-calmodulin-dependent protein kinase gene expression in the adult monkey visual cortex [published erratum appears in J Neurosci 1991 May;11(5):following Table of Contents] , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[54] T. McCown. Adeno-Associated Virus (AAV) Vectors in the CNS. , 2005, Current gene therapy.
[55] B. Davidson,et al. Transduction of murine cerebellar neurons with recombinant FIV and AAV5 vectors , 2000, Neuroreport.
[56] N. Déglon,et al. Viral vectors as tools to model and treat neurodegenerative disorders , 2005, The journal of gene medicine.
[57] KouichiC . Nakamura,et al. Efficient gene transduction of neurons by lentivirus with enhanced neuron-specific promoters , 2007, Gene Therapy.
[58] J. Verhaagen,et al. Viral vectors, tools for gene transfer in the nervous system , 1998, Progress in Neurobiology.
[59] R. Samulski,et al. Viral vectors for gene delivery to the central nervous system , 2012, Neurobiology of Disease.
[60] K. Obata,et al. Preferential labeling of inhibitory and excitatory cortical neurons by endogenous tropism of adeno-associated virus and lentivirus vectors , 2009, Neuroscience.
[61] Edilson Ervolino,et al. Cyto-, myelo- and chemoarchitecture of the prefrontal cortex of the Cebus monkey , 2011, BMC Neuroscience.
[62] Zeger Debyser,et al. Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. , 2007, Human gene therapy.
[63] F. Coun,et al. Efficient and stable transduction of dopaminergic neurons in rat substantia nigra by rAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9 , 2011, Gene Therapy.
[64] J. Bloch,et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.
[65] R. Samulski,et al. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. , 2004, Annual review of genetics.
[66] E. G. Jones,et al. Localization of alpha type II calcium calmodulin-dependent protein kinase at glutamatergic but not gamma-aminobutyric acid (GABAergic) synapses in thalamus and cerebral cortex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[67] Mehrdad Jazayeri,et al. Saccadic eye movements evoked by optogenetic activation of primate V1 , 2012, Nature Neuroscience.
[68] J. Malpeli,et al. The representation of the visual field in the lateral geniculate nucleus of Macaca mulatta , 1975, The Journal of comparative neurology.
[69] J. Uney,et al. Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells) , 2009, Cell Biology and Toxicology.
[70] M. King,et al. Dose and Promoter Effects of Adeno-Associated Viral Vector for Green Fluorescent Protein Expression in the Rat Brain , 2002, Experimental Neurology.
[71] V. Choi,et al. AAV hybrid serotypes: improved vectors for gene delivery. , 2005, Current gene therapy.
[72] Lief E. Fenno,et al. Amygdala circuitry mediating reversible and bidirectional control of anxiety , 2011, Nature.
[73] R. Barker,et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial , 2014, The Lancet.
[74] Nathan C. Klapoetke,et al. A High-Light Sensitivity Optical Neural Silencer: Development and Application to Optogenetic Control of Non-Human Primate Cortex , 2010, Front. Syst. Neurosci..
[75] L. Arckens,et al. Evaluation of the expression pattern of rAAV2/1, 2/5, 2/7, 2/8, and 2/9 serotypes with different promoters in the mouse visual cortex , 2015, The Journal of comparative neurology.
[76] R. Samulski,et al. Cross-Packaging of a Single Adeno-Associated Virus (AAV) Type 2 Vector Genome into Multiple AAV Serotypes Enables Transduction with Broad Specificity , 2002, Journal of Virology.
[77] Karl Deisseroth,et al. Controlling the brain with light , 2010 .
[78] B. Roth,et al. Remote Control of Neuronal Signaling , 2011, Pharmacological Reviews.
[79] Krystof S. Bankiewicz,et al. ADENO-ASSOCIATED VIRUS TYPE 6 IS RETROGRADELY TRANSPORTED IN THE NON-HUMAN PRIMATE BRAIN , 2013, Gene Therapy.
[80] Matt Wachowiak,et al. Transgene Expression in Target-Defined Neuron Populations Mediated by Retrograde Infection with Adeno-Associated Viral Vectors , 2013, The Journal of Neuroscience.
[81] E G Jones,et al. Cell- and Lamina-Specific Expression and Activity-Dependent Regulation of Type II Calcium/Calmodulin-Dependent Protein Kinase Isoforms in Monkey Visual Cortex , 1998, The Journal of Neuroscience.
[82] John F Neumaier,et al. Grateful DREADDs: Engineered Receptors Reveal How Neural Circuits Regulate Behavior , 2012, Neuropsychopharmacology.